{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:33:09Z","timestamp":1793075589854,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jlb.2026.100669","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:36Z","timestamp":1790837076000},"page":"100669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors"],"prefix":"10.1016","volume":"14","author":[{"given":"Atri","family":"Choksi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany E.","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaia","family":"Florou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kansas","family":"Krabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100669_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.jlb.2026.100669_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae344","article-title":"Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"30","author":"Leite da Silva","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.jlb.2026.100669_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jlb.2026.100669_bib4","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100669_bib5","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100669_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41698-026-01327-y","article-title":"Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab","volume":"10","author":"Stutheit-Zhao","year":"2026","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100669_bib7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jlb.2026.100669_bib8","doi-asserted-by":"crossref","first-page":"1172108","DOI":"10.3389\/fgene.2023.1172108","article-title":"Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.jlb.2026.100669_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100669_bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100669_bib11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ajcp\/aqv023","article-title":"Identification of factors affecting the success of next-generation sequencing testing in solid tumors","volume":"145","author":"Goswami","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jlb.2026.100669_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5858\/arpa.2021-0313-OA","article-title":"Method of tissue acquisition affects success of comprehensive genomic profiling in lung cancer","volume":"147","author":"Mata","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jlb.2026.100669_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100669_bib14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100669_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.aai8515","article-title":"Origins of lymphatic and distant metastases in human colorectal cancer","volume":"357","author":"Naxerova","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jlb.2026.100669_bib16","doi-asserted-by":"crossref","first-page":"14944","DOI":"10.1038\/ncomms14944","article-title":"Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations","volume":"8","author":"Brown","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jlb.2026.100669_bib17","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jlb.2026.100669_bib18","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1038\/s41598-025-90013-3","article-title":"Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring","volume":"15","author":"Ye","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jlb.2026.100669_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.tibtech.2024.12.003","article-title":"Absolute quantification of cell-free DNA for prenatal genetics and oncology","volume":"43","author":"Tsao","year":"2025","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jlb.2026.100669_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Software"},{"key":"10.1016\/j.jlb.2026.100669_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jlb.2026.100669_bib33","article-title":"Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection","volume":"5","author":"Jimenez-Munarriz","year":"2026","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.jlb.2026.100669_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cllc.2024.10.013","article-title":"Brief report: methylation-based ctDNA serial monitoring correlates with immunotherapy response in NSCLC","volume":"26","author":"Hsiao","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jlb.2026.100669_bib22","first-page":"1525","article-title":"Longitudinal analyses of circulating tumor DNA for the detection of EGFR mutation-positive advanced NSCLC progression during treatment: data from FLAURA and AURA3","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.jlb.2026.100669_bib23","first-page":"1568","article-title":"Early circulating tumor DNA dynamics and efficacy of lorlatinib in patients with treatment-naive, advanced, ALK-positive NSCLC","volume":"18","author":"Soo","year":"2023","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.jlb.2026.100669_bib24","doi-asserted-by":"crossref","first-page":"100477","DOI":"10.1016\/j.jlb.2026.100477","article-title":"Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors","volume":"13","author":"Anees","year":"2026","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.jlb.2026.100669_bib25","doi-asserted-by":"crossref","first-page":"71887","DOI":"10.18632\/oncotarget.12114","article-title":"Receptor conversion in metastatic breast cancer: a prognosticator of survival","volume":"7","author":"Meng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jlb.2026.100669_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","article-title":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","volume":"52","author":"Hu","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jlb.2026.100669_bib27","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216505","article-title":"Comparison of tumor\u2010informed and tumor\u2010na\u00efve sequencing assays for ctDNA detection in breast cancer","volume":"15","author":"Santonja","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jlb.2026.100669_bib28","doi-asserted-by":"crossref","first-page":"1055968","DOI":"10.3389\/fonc.2022.1055968","article-title":"Tumor-informed or tumor-agnostic circulating tumor DNA as a biomarker for risk of recurrence in resected colorectal cancer patients","volume":"12","author":"Chan","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jlb.2026.100669_bib29","article-title":"Real-world validity of tissue-agnostic circulating tumor DNA response monitoring in lung cancers treated with chemotherapy, immunotherapy, or targeted agents","volume":"6","author":"Chiang","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jlb.2026.100669_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jlb.2026.100669_bib31","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426002158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426002158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:00:21Z","timestamp":1793073621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426002158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S2950195426002158"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100669","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100669"}}